ABCL vs. SGMO

Last updated Jun 4, 2026

ABCL (AbCellera Biologics Inc.) and SGMO (Sangamo Therapeutics, Inc.) are both stocks. Both operate in the Biotechnology industry within the Healthcare sector. Over the past 5 years, ABCL returned -26.11%/yr vs -54.34%/yr for SGMO. At a 0.35 correlation, their price movements are largely independent.

Performance

ABCL vs. SGMO - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in AbCellera Biologics Inc. (ABCL) and Sangamo Therapeutics, Inc. (SGMO). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

In the year-to-date period, ABCL achieves a 67.25% return, which is significantly higher than SGMO's -48.52% return.

ABCL

• 1D: -6.69%
• 1M: 24.62%
• YTD: 67.25%
• 6M: 63.90%
• 1Y: 147.62%
• 3Y*: -5.56%
• 5Y*: -26.11%
• 10Y*: —

SGMO

• 1D: 1.03%
• 1M: 21.73%
• YTD: -48.52%
• 6M: -56.70%
• 1Y: -56.78%
• 3Y*: -42.71%
• 5Y*: -54.34%
• 10Y*: -29.44%

*Multi-year figures are annualized to reflect compound growth (CAGR)

ABCL vs. SGMO - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020
ABCL AbCellera Biologics Inc.	67.25%	16.72%	-48.69%	-43.63%	-29.16%	-64.46%	-31.68%
SGMO Sangamo Therapeutics, Inc.	-48.52%	-58.82%	87.74%	-82.70%	-58.13%	-51.94%	27.08%

Correlation

The correlation between ABCL and SGMO is 0.30, which is low. Their price movements are largely independent, making them effective diversification partners.

	Correlation
Correlation (1Y) Calculated over the trailing 1-year period	0.30
Correlation (3Y) Calculated over the trailing 3-year period	0.32
Correlation (5Y) Calculated over the trailing 5-year period	0.37
Correlation (All Time) Calculated using the full available price history since Dec 14, 2020	0.35

Fundamentals

Market Cap ABCL : $1.73B SGMO : $84.23M
EPS ABCL : -$0.48 SGMO : -$0.38
PS Ratio ABCL : 21.65 SGMO : 2.02
Total Revenue (TTM) ABCL : $79.21M SGMO : $34.56M
Gross Profit (TTM) ABCL : $70.89M SGMO : $25.51M
EBITDA (TTM) ABCL : -$166.07M SGMO : -$106.29M

Return for Risk

ABCL vs. SGMO — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

ABCL

ABCL Risk / Return Rank: 81
ABCL Sharpe Ratio Rank: 87
ABCL Sortino Ratio Rank: 84
ABCL Omega Ratio Rank: 79
ABCL Calmar Ratio Rank: 80
ABCL Martin Ratio Rank: 74

SGMO

SGMO Risk / Return Rank: 21
SGMO Sharpe Ratio Rank: 22
SGMO Sortino Ratio Rank: 29
SGMO Omega Ratio Rank: 29
SGMO Calmar Ratio Rank: 17
SGMO Martin Ratio Rank: 9

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

ABCL vs. SGMO - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for AbCellera Biologics Inc. (ABCL) and Sangamo Therapeutics, Inc. (SGMO). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	ABCL	SGMO	Difference
Sharpe ratio: Return per unit of total volatility	1.88	-0.45	+2.33
Sortino ratio: Return per unit of downside risk	2.61	-0.03	+2.64
Omega ratio: Gain probability vs. loss probability	1.30	1.00	+0.30
Calmar ratio: Return relative to maximum drawdown	2.70	-0.66	+3.36
Martin ratio: Return relative to average drawdown	4.94	-1.35	+6.29
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

ABCL vs. SGMO - Sharpe Ratio Comparison

The current ABCL Sharpe Ratio is 1.88, which is higher than the SGMO Sharpe Ratio of -0.45. The chart below compares the historical Sharpe Ratios of ABCL and SGMO, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.

Sharpe Ratios by Period

	ABCL	SGMO	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	1.88	-0.45	+2.33
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	-0.39	-0.48	+0.09
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	—	-0.30	—
Sharpe Ratio (All Time) Calculated using the full available price history	-0.50	-0.17	-0.33

Drawdowns

ABCL vs. SGMO - Drawdown Comparison

The maximum ABCL drawdown since its inception was -96.72%, roughly equal to the maximum SGMO drawdown of -99.80%. Use the drawdown chart below to compare losses from any high point for ABCL and SGMO.

Drawdown Indicators

	ABCL	SGMO	Difference
Max Drawdown Largest peak-to-trough decline	-96.72%	-99.80%	+3.08%
Max Drawdown (1Y) Largest decline over 1 year	-54.94%	-86.32%	+31.38%
Max Drawdown (3Y) Largest decline over 3 years	-75.72%	-96.48%	+20.76%
Max Drawdown (5Y) Largest decline over 5 years	-92.64%	-99.17%	+6.53%
Max Drawdown (10Y) Largest decline over 10 years	—	-99.62%	—
Current Drawdown Current decline from peak	-90.29%	-99.56%	+9.27%
Average Drawdown Average peak-to-trough decline	-83.59%	-84.03%	+0.44%
Ulcer Index Depth and duration of drawdowns from previous peaks	30.01%	42.00%	-11.99%

Volatility

ABCL vs. SGMO - Volatility Comparison

The current volatility for AbCellera Biologics Inc. (ABCL) is 28.65%, while Sangamo Therapeutics, Inc. (SGMO) has a volatility of 66.89%. This indicates that ABCL experiences smaller price fluctuations and is considered to be less risky than SGMO based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	ABCL	SGMO	Difference
Volatility (1M) Calculated over the trailing 1-month period	28.65%	66.89%	-38.24%
Volatility (6M) Calculated over the trailing 6-month period	52.34%	116.30%	-63.96%
Volatility (1Y) Calculated over the trailing 1-year period	79.56%	125.75%	-46.19%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	66.48%	112.76%	-46.28%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	70.07%	98.49%	-28.42%

Dividends

ABCL vs. SGMO - Dividend Comparison

Neither ABCL nor SGMO has paid dividends to shareholders.

Tickers have no history of dividend payments

Financials

Frequently Asked Questions

Can I hold both ABCL and SGMO in my portfolio?

ABCL and SGMO have a correlation of 0.30, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

Which is riskier, ABCL or SGMO?

SGMO has higher volatility (66.89%) compared to ABCL (28.65%). In terms of maximum drawdown, ABCL dropped -96.72% vs SGMO's -99.80%.

Which has better risk-adjusted returns?

ABCL currently has the higher Sharpe Ratio (1.88 vs -0.45), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.